These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 11228338)

  • 1. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
    Elg M; Carlsson S; Gustafsson D
    Thromb Res; 2001 Feb; 101(3):145-57. PubMed ID: 11228338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits.
    Elg M; Carlsson S; Gustafsson D
    Thromb Res; 2001 Feb; 101(3):159-70. PubMed ID: 11228339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate.
    Sørensen B; Ingerslev J
    Thromb Haemost; 2006 Oct; 96(4):446-53. PubMed ID: 17003921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
    Wolzt M; Levi M; Sarich TC; Boström SL; Eriksson UG; Eriksson-Lepkowska M; Svensson M; Weitz JI; Elg M; Wåhlander K
    Thromb Haemost; 2004 Jun; 91(6):1090-6. PubMed ID: 15175794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates.
    Gruber A; Carlsson S; Kotzé HF; Marzec U; Sarich TC; Hanson SR
    Thromb Res; 2007; 119(1):121-7. PubMed ID: 16448687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma.
    Koestenberger M; Gallistl S; Muntean W; Leschnik B; Fritsch P; Cvirn G
    Thromb Haemost; 2005 Jul; 94(1):69-74. PubMed ID: 16113786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
    Perzborn E; Heitmeier S; Laux V; Buchmüller A
    Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents.
    Fukuda T; Honda Y; Kamisato C; Morishima Y; Shibano T
    Thromb Haemost; 2012 Feb; 107(2):253-9. PubMed ID: 22186946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates.
    Perzborn E; Gruber A; Tinel H; Marzec UM; Buetehorn U; Buchmueller A; Heitmeier S; Laux V
    Thromb Haemost; 2013 Jul; 110(1):162-72. PubMed ID: 23636219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo reversal of the anticoagulant effects of edoxaban.
    Halim AB; Samama MM; Mendell J
    Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation.
    Dickneite G
    Thromb Res; 2007; 119(5):643-51. PubMed ID: 16842841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
    Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
    Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time.
    Koestenberger M; Cvirn G; Gallistl S; Muntean W
    Blood Coagul Fibrinolysis; 2004 Oct; 15(8):693-7. PubMed ID: 15613925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample.
    Mattsson C; Menschiek-Lundin A; Wåhlander K; Lindahl TL
    Thromb Haemost; 2001 Aug; 86(2):611-5. PubMed ID: 11522011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of thrombin-induced feedback activation of factor V: a potential pathway for inhibition of thrombin generation by melagatran.
    Boström SL; Dagnelid E; Hansson GF; Ulvinge JC
    Blood Coagul Fibrinolysis; 2004 Jan; 15(1):25-30. PubMed ID: 15166940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination.
    Koestenberger M; Gallistl S; Cvirn G; Baier K; Leschnik B; Muntean W
    Thromb Res; 2005; 115(1-2):135-42. PubMed ID: 15567465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.
    Mehta JL; Chen L; Nichols WW; Mattsson C; Gustafsson D; Saldeen TG
    J Cardiovasc Pharmacol; 1998 Mar; 31(3):345-51. PubMed ID: 9514177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats.
    Carlsson S; Elg M; Mattsson C
    Thromb Res; 2002 Aug; 107(3-4):163-8. PubMed ID: 12431484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid.
    Fager G; Cullberg M; Eriksson-Lepkowska M; Frison L; Eriksson UG
    Eur J Clin Pharmacol; 2003 Aug; 59(4):283-9. PubMed ID: 12845508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.